Navigation Links
Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
Date:7/24/2008

ST. LOUIS, July 24 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) announced today that it has received regulatory approvals for Roundup Ready 2 Yield(TM) soybeans in Mexico, Australia and New Zealand. In addition, the company noted the European Food Safety Authority (EFSA) has issued a positive scientific opinion concluding Roundup Ready 2 Yield is safe for import as food or feed. Roundup Ready 2 Yield soybeans are the second generation of the popular Roundup Ready(R) technology in soybeans and offer increased yields.

"These regulatory decisions by Mexico and Europe represent significant steps forward in delivering Roundup Ready 2 Yield soybeans to our customers," according to Brett Begemann, Monsanto's executive vice president of global commercial business. "Farmers have used Roundup Ready(R) soybeans for more than 10 years to achieve unsurpassed weed control. Roundup Ready 2 Yield soybeans have increased yields, and will advance farmers' ability to meet the world's growing food, feed and fuel needs."

Roundup Ready 2 Yield soybeans have now been approved in the United States, Canada, Mexico, Taiwan, Japan, the Philippines, Australia and New Zealand, says Jerry Hjelle, Monsanto's regulatory vice president.

"These recent approvals add to the list of countries that have reviewed and concluded that Roundup Ready 2 Yield soybeans are safe," he explains. "The positive EFSA opinion on safety is an important step toward gaining approval within the European Union. Moreover, we are working diligently to achieve regulatory clearance in other markets in anticipation of a 2009 release."

In four years of testing, Roundup Ready 2 Yield soybeans have demonstrated a consistent yield advantage of 7 percent to 11 percent when compared with its predecessor, Roundup Ready soybeans. The four-year average yield increase of Roundup Ready 2 Yield over its first-generation counterpart was 9 percent.

Monsanto's Roundup Ready 2 Yield soybeans
'/>"/>

SOURCE Monsanto Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
2. Monsanto Company and Mendel Biotechnology Announce Cellulosic Biofuels Collaboration
3. Monsanto Executives to Address Investor Conferences in February
4. National Academy of Sciences Recognizes Monsantos Chief Technology Officer for Development of Agricultural Biotechnology
5. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
6. Monsanto and Devgen Describe New Approach to Insect-Protection
7. Monsanto Company Executives Adopt 10b5-1 Trading Plans
8. Science Magazine Recognizes Monsanto as Top Employer
9. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
10. Monsanto Company Sets Webcast and Analyst/Media Call for 2007 Fourth-Quarter and Fiscal-Year Financial Results
11. Monsanto and Evogene Collaborate on Nitrogen Use Efficiency Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... to present at 2008 BIO CEO & Investor conference at ... New York on Tuesday, February 12 at 1:15 PM (Eastern), ... -- James A. Bianco, M.D., President and CEO of Cell,Therapeutics, ... overview of,the Company,s sales and marketing strategy intended to grow ...
... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... and interpretation services including,expert consultation and a ... capture and electronic patient reported outcomes,solutions), announced ... fourth quarter,results for the period ended December ...
... CHICAGO, Feb. 11 Advanced Life Sciences,Holdings, Inc. ... in the,discovery, development and commercialization of novel drugs ... diseases today,announced that it will host a conference ... and full-year financial results on Tuesday,February 19 at ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 3
(Date:8/19/2014)... German . , , ... of plants can switch off individual genes and study ... Planck Institute for Plant Breeding Research in Cologne and ... different approach. They identify small molecules that block specific ... prevent the downstream reactions. In their search for these ...
(Date:8/19/2014)... young have bigger brains than counterparts that don,t care ... study. , Stickleback fish are well known in the ... the species, rather than the female, cares for offspring. ... researchers wanted to find out if the difference in ... , In the study, published recently in Ecology ...
(Date:8/18/2014)... Ariz. Half of the Earth,s land mass is ... yet they are being transformed at an alarming rate. ... in and taking over, leading to a loss of ... ability of ecosystems to produce food specifically meat. ... Life Sciences led an investigation that quantified this loss ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... N.Y. Proteins are critically important to life and the ... in nature, and there is much we still don,t know ... the stability of enzymes, a particular type of protein that ... natural environment in the cell or body, enzymes can quickly ...
... that nanoparticles, which are now present in everything from ... irreparably damaging effects on soil systems and the environment. ... every year, including silver nanoparticles which are popular as ... Department of Biology. "We started to wonder what the ...
... (April 6, 2011) -- A new drug delivery device ... Peter Rentzepis promises to unlock the potential of photosensitive ... as well. Photosensitive chemicals are molecules that ... These radicals are very active chemically, and can rip ...
Cached Biology News:Nano fit-ness: Helping enzymes stay active and keep in shape 2Common nanoparticles found to be highly toxic to Arctic ecosystem 2New device promises safer way to deliver powerful drugs 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
... Immunogen: Peptide corresponding ... human, mouse, and rat phospho-FAK (Ser843) ... NM_153831 Quality ... Molecular Weight: ...
Biology Products: